Endosaccular flow disruption: where are we now?

Endosaccular flow disruption is an innovative method of treating wide-necked complex aneurysms. Currently four types of devices have obtained the CE mark for use within Europe. These are the Woven EndoBridge device (WEB), the Luna Aneurysm Embolization System, the Medina Embolic Device (Medtronic), and the Contour Neurovascular System. The aim of this article is to provide an overview of these devices and to summarize the evidence in the literature pertaining to the treatment of intracranial aneurysms with them.
Competing Interests: Competing interests: PBh: consultant for phenox. CC: consultant for Stryker, Medtronic, Cerenovus and Microvention. MP: consultant for Medtronic, Stryker, MicroVention, Balt, Penumbra, Base Camp Vascular (share holder). N-AS: investor in Medina. PBr: consultant for Cerenovus. TA: consultant for Ablynx, Amnis Therapeutics, Anaconda, Cerenovus–Neuravi, Medtronic-Covidien, Rapid Medical. DF: consultant for Medtronic, Microvention, Penumbra, Balt, Cerenovus, Stryker; research support: Siemens, Microvention, Penumbra, Cerenovus; stockholder: Marblehead, Neurogami, Vascular Simulations; board member: Vascular Simulations. ASA: consultant for Balt, Johnson and Johnson, Leica, Medtronic, Microvention, Penumbra, Scientia, Siemens, Stryker; shareholder in Bendit, Cerebrotech, Endostream, Magneto, Marblehead, Neurogami, Serenity, Synchron, Triad Medical, Vascular Simulations. MS: consultant for Cerenovus and Archer Research. HH: co-founder and shareholder for phenox GmbH and femtos GmbH. LP: consultant for Balt, Cerus Endovascular, MicroVention, Phenox, Vesalio, Penumbra.
(© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)